ClinicalTrials.gov
ClinicalTrials.gov Menu

Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00899119
Recruitment Status : Unknown
Verified January 2008 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : May 12, 2009
Last Update Posted : December 18, 2013
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

May 9, 2009
May 12, 2009
December 18, 2013
November 2005
Not Provided
Number of days to adequate stem cell harvest
Same as current
Complete list of historical versions of study NCT00899119 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia
Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia

RATIONALE: Collecting and storing stem cells to study in the laboratory may help doctors learn more about collecting stem cells from patients who have undergone treatment for Waldenstrom's macroglobulinemia.

PURPOSE: This laboratory study is collecting stem cells from patients with Waldenstrom's macroglobulinemia.

OBJECTIVES:

  • Harvest and store adequate CD34+ stem cells from patients with Waldenstrom's macroglobulinemia (WM) for potential future use in transplantation strategies.
  • Evaluate the ability to harvest stem cells after therapy for WM (e.g., fludarabine-based chemotherapy) by evaluating the number of days to adequate harvest.
  • Collect aliquots of stem cells for future research analysis as part of a WM database project.

OUTLINE: Patients undergo collection of autologous stem cells beginning on day 4 or 5 and continuing until an adequate number of stem cells are collected. Cells are then cryopreserved.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Lymphoma
Procedure: leukapheresis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
40
Same as current
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Diagnosis of Waldenstrom's macroglobulinemia (WM)
  • Less than 30% lymphoplasmacytoid cells in bone marrow by histopathology
  • Received prior chemotherapy for WM

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-1
  • WBC > 2,000/mm³
  • Platelet count > 50,000/mm³
  • LVEF ≥ 50%
  • No organ dysfunction that would preclude future transplantation

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00899119
CDR0000487602
CPMC-AAAB4806
Not Provided
Not Provided
Not Provided
Not Provided
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Gwen L. Nichols, MD Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)
January 2008